Bayer's €375 Million Stivarga Exit and a $7.25 Billion Missouri Settlement Bid Put Two Clocks on the Same Stock
Published on 09/22/2026 at 18:02 | Editorial boerse-global.de
Bayer is simultaneously winding down one chapter of its oncology portfolio and trying to close a far costlier legal one. The Leverkusen-based life sciences group has agreed to hand worldwide rights to its cancer drug Stivarga to Grünenthal, a deal worth as much as €375 million to Bayer, while its Monsanto unit presses a Missouri court to approve a $7.25 billion settlement covering tens of thousands of US lawsuits.
A mature asset changes hands
Stivarga is the brand name for regorafenib, an oral multikinase inhibitor taken once daily. It is approved for metastatic colorectal cancer, hepatocellular carcinoma and gastrointestinal stromal tumors following prior therapy. More than one million patients across over 90 countries have received the treatment over the past decade.
For Bayer, the sale represents an orderly exit from a product whose growth phase has run its course. In fiscal 2025, Stivarga revenue fell 27% to €338 million. Generic competition is expected in Europe from 2029 and in the US from 2030, putting a firm horizon on the drug's remaining exclusivity.
The transaction still requires customary regulatory clearances, with the parties targeting completion in late 2026 or early 2027. Grünenthal, the buyer, continues its run of acquisitions and expects full consolidation of Stivarga to contribute up to €100 million in EBITDA in fiscal 2027.
Should investors sell immediately? Or is it worth buying Bayer?
Proceeds from the divestment give Bayer cash from a mature medicine before patent protection lapses, allowing management to sharpen its focus on newer oncology development programs.
Missouri becomes the decisive venue
The larger swing factor sits in a US courtroom. Monsanto filed on September 14 with a court in Missouri seeking approval of a $7.25 billion settlement aimed at resolving a substantial portion of a long-running legal complex. According to Reuters, the agreement targets tens of thousands of US claims, with tiered payouts ranging from $10,000 to $165,000 for certain plaintiffs.
For shareholders, the stakes are hard to overstate. The US litigation has weighed on the Leverkusen group for years and consumed significant management bandwidth. The central question now is whether $7.25 billion is enough to draw a reliable line under the claims. The sum represents a substantial outflow that would leave a visible mark on the balance sheet, set against the potential gain in planning certainty. As long as damage awards carry unpredictable financial risk, the market struggles to value the operating business with confidence.
Pipeline momentum on two fronts
Progress in the pharmaceutical division has continued regardless of the legal overhang. Bayer secured two US approvals: accelerated FDA clearance for sevabertinib as a first-line therapy in HER2-mutated non-small cell lung cancer, and an approval for finerenone in chronic kidney disease associated with type 1 diabetes. The FDA also broadened the Kerendia label more than a month ago.
In agriculture, the company is laying longer-term groundwork. Subsidiary Robigo and Leaps by Bayer announced a Series A financing aimed at developing genetically engineered biological products designed to protect yields and lower farming costs. In a calmer legal environment, such development steps could regain more leverage in the share price.
What could still go wrong
The optimistic scenario carries a tangible downside. If the proposed settlement fails to win judicial approval, the burden remains undiminished. US courts scrutinize class-wide settlements strictly, particularly around the protection of future or dissenting claims.
The structure of the payouts also invites friction. Plaintiffs unwilling to accept sums between $10,000 and $165,000 could try to pursue claims outside the settlement. Should a meaningful number of claimants reject the deal, the risk of further costly individual trials would not be extinguished. A rejection by the Missouri court would return the company to the status quo ante, with uncertainty over the true total liability back in full force and the recent share price advance called into question.
Bayer at a turning point? This analysis reveals what investors need to know now.
Where the stock stands
The market has already begun pricing in the hope of a foreseeable end to the litigation. Bayer shares changed hands at €48.90, up 32% since the start of the year. In a separate reading of the same session, the stock stood at €49.41, a gain of 34% year-to-date and 8.3% below its 52-week high.
That recovery now hinges on whether the settlement is confirmed by the bench and accepted by a sufficiently large share of claimants. A green light from Missouri would strip the group's single biggest valuation drag of much of its weight, clearing the way for investors to refocus on the operating story. A veto, or broad resistance among plaintiff groups, would push legal risk back to the foreground and expose shareholders to renewed valuation discounts as lengthy negotiations and unpredictable jury verdicts resume.
The next catalyst is therefore narrowly defined: the Missouri court's ruling on the approval motion. That decision determines whether Bayer's breakout succeeds or the stalemate rolls into another round.
Ad
Bayer Stock: New Analysis - 22 September
Fresh Bayer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
